Lori Minasian
Overview
Explore the profile of Lori Minasian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lavik E, Minasian L
Bioconjug Chem
. 2024 Aug;
35(8):1148-1153.
PMID: 39116257
Cancer prevention encompasses both screening strategies to find cancers early when they are likely to be most treatable and prevention and interception strategies to reduce the risk of developing cancers....
2.
Janse van Rensburg H, Liu Z, Watson G, Veitch Z, Shepshelovich D, Spreafico A, et al.
Br J Cancer
. 2023 Jul;
129(4):612-619.
PMID: 37419999
Background: Patient perspectives are fundamental to defining tolerability of investigational anti-neoplastic therapies in clinical trials. Phase I trials present a unique challenge in designing tools for efficiently collecting patient-reported outcomes...
3.
Basch E, Dueck A, Mitchell S, Mamon H, Weiser M, Saltz L, et al.
J Clin Oncol
. 2023 Jun;
41(21):3724-3734.
PMID: 37270691
Purpose: The standard of care for locally advanced rectal cancer in North America is neoadjuvant pelvic chemoradiation with fluorouracil (5FUCRT). Neoadjuvant chemotherapy with fluorouracil and oxaliplatin (FOLFOX) is an alternative...
4.
Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, et al.
J Natl Cancer Inst
. 2023 Jan;
115(4):437-446.
PMID: 36625510
Background: An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL...
5.
Watson G, Veitch Z, Shepshelovich D, Liu Z, Spreafico A, Abdul Razak A, et al.
Br J Cancer
. 2022 Aug;
127(9):1629-1635.
PMID: 36008705
Background: Adverse event (AE) reporting in early-phase clinical trials is essential in determining the tolerability of experimental anticancer therapies. The patient-reported outcome version of the CTCAE (PRO-CTCAE) evaluates AE components...
6.
Ruan E, Nemeth E, Moffitt R, Sandoval L, Machiela M, Freedman N, et al.
Bioinformatics
. 2022 Jul;
38(18):4434-4436.
PMID: 35900159
Motivation: The Division of Cancer Epidemiology and Genetics (DCEG) and the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) have recently generated genome-wide association study (GWAS) data...
7.
Freedman A, Klabunde C, Wiant K, Enewold L, Gray S, Filipski K, et al.
JCO Precis Oncol
. 2022 Feb;
2.
PMID: 35135159
Purpose: There are no nationally representative data on oncologists' use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the United...
8.
Pinsky P, Goodman P, Parnes H, Ford L, Minasian L
Prev Med
. 2021 Aug;
153:106778.
PMID: 34450188
Several studies have shown that non-adherence to medication use is associated with lower use of preventive services and increased mortality. We aimed to study the relationship between initial adherence to...
9.
Janelsins M, Mohamed M, Peppone L, Magnuson A, Belcher E, Melnik M, et al.
J Natl Cancer Inst
. 2021 Jul;
114(1):47-59.
PMID: 34255086
Background: Cancer-related cognitive decline (CRCD) is an important clinical problem, but limited research exists on assessment of cognitive function in patients with lymphoma. Methods: The overall objective of this nationwide,...
10.
Veitch Z, Shepshelovich D, Gallagher C, Wang L, Abdul Razak A, Spreafico A, et al.
J Natl Cancer Inst
. 2021 Feb;
113(8):980-988.
PMID: 33616650
Background: Clinician reporting of symptomatic adverse events (AEs) in phase I trials uses the Common Terminology Criteria for Adverse Events (CTCAE). The utility of the patient-reported outcomes (PROs) version of...